FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
This article was originally published in The Tan Sheet
Executive Summary
FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register
You may also be interested in...
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8